DC Underwood, RR Osborn, SJ Newsholme, TJ Torphy and DW Hay
Department of Pulmonary Pharmacology and Toxicology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania, USA.

Aerosolized cysteinyl leukotrienes (CysLTs) elicit migration of eosinophils into guinea pig lungs and the airways of patients with asthma. The present studies were designed to analyze the concentration- response relationship, time course, and pharmacologic and histologic characteristics of leukotriene D4 (LTD4)-induced eosinophil influx into the airways of conscious guinea pigs. Animals were exposed to aerosols of 0.3 to 30 microg/ml LTD4 for 1 min, during which specific airway conductance (sGaw) was monitored. Bronchoalveolar lavages (BALs) of guinea pig airways were conducted at selected times from 4 h to 4 wk after LTD4 challenge. LTD4 produced maximal decreases in sGaw (70 to 90% reduction) at all concentrations tested and concentration-related increases in eosinophil levels in BALs, assessed 24 h after challenge. Increased numbers of eosinophils in the bronchial epithelium and subepithelium were confirmed histologically. Significant eosinophilia was maintained for up to 4 wk postchallenge. Pretreatment with the LTD4 receptor antagonist, pranlukast (ONO-1078, SB 205312) (20 mg/kg, intragastrically), significantly inhibited both the bronchoconstriction and the eosinophilia at 24 h, whereas the cyclooxygenase inhibitor, meclofenamic acid (5 mg/kg, intragastrically), had no effect on either parameter. Histologic observations were consistent with BAL results. Pretreatment with the rat anti-mouse antibody to interleukin-5 (IL-5), TRFK-5 (10-300 microg, intraperitoneally), produced dose-related inhibition of LTD4-induced eosinophilia, measured in 24 h or 3 wk BAL, but did not affect the acute bronchoconstriction. These results indicate that LTD4 elicits airway eosinophil influx in guinea pigs which persists as long as 4 wk after a single exposure, and provide the first evidence that IL-5 may have a role in LTD4-induced airways inflammation. This and other previously reported proinflammatory effects of LTD4 may contribute significantly to its overall influential role in the pathophysiology of asthma, and may underlie the therapeutic benefit of CysLT receptor antagonists, such as pranlukast, in this disorder.

This article has been cited by other articles:

				Y. Shiraishi, K. Asano, K. Niimi, K. Fukunaga, M. Wakaki, J. Kagyo, T. Takihara, S. Ueda, T. Nakajima, T. Oguma, et al. Cyclooxygenase-2/Prostaglandin D2/CRTH2 Pathway Mediates Double-Stranded RNA-Induced Enhancement of Allergic Airway Inflammation J. Immunol., January 1, 2008; 180(1): 541 - 549. [Abstract] [Full Text] [PDF]

				K. Parameswaran, R. Watson, G. M. Gauvreau, R. Sehmi, and P. M. O'Byrne The Effect of Pranlukast on Allergen-induced Bone Marrow Eosinophilopoiesis in Subjects with Asthma Am. J. Respir. Crit. Care Med., April 15, 2004; 169(8): 915 - 920. [Abstract] [Full Text] [PDF]

				M. Ishiwara, Y. Aoki, H. Takagaki, M. Ui, and F. Okajima TA-270 [4-Hydroxy-1-methyl-3-octyloxy-7-sinapinoylamino-2(1H)-quinolinone], an Anti-Asthmatic Agent, Inhibits Leukotriene Production Induced by IgE Receptor Stimulation in RBL-2H3 Cells J. Pharmacol. Exp. Ther., November 1, 2003; 307(2): 583 - 588. [Abstract] [Full Text] [PDF]

				K. Chibana, Y. Ishii, T. Asakura, and T. Fukuda Up-Regulation of Cysteinyl Leukotriene 1 Receptor by IL-13 Enables Human Lung Fibroblasts to Respond to Leukotriene C4 and Produce Eotaxin J. Immunol., April 15, 2003; 170(8): 4290 - 4295. [Abstract] [Full Text] [PDF]

				C. Brink, S.-E. Dahlen, J. Drazen, J. F. Evans, D. W. P. Hay, S. Nicosia, C. N. Serhan, T. Shimizu, and T. Yokomizo International Union of Pharmacology XXXVII. Nomenclature for Leukotriene and Lipoxin Receptors Pharmacol. Rev., March 1, 2003; 55(1): 195 - 227. [Abstract] [Full Text] [PDF]

				W. M. Abraham Of Mice and Men Am. J. Respir. Cell Mol. Biol., January 1, 2003; 28(1): 1 - 4. [Full Text] [PDF]

				S.-Y. Eum, K. Maghni, Q. Hamid, H. Campbell, D. H. Eidelman, and J. G. Martin Involvement of the Cysteinyl-Leukotrienes in Allergen-Induced Airway Eosinophilia and Hyperresponsiveness in the Mouse Am. J. Respir. Cell Mol. Biol., January 1, 2003; 28(1): 25 - 32. [Abstract] [Full Text] [PDF]

				S. Nag, B. Lamkhioued, and P. M. Renzi Interleukin-2-induced Increased Airway Responsiveness and Lung Th2 Cytokine Expression Occur after Antigen Challenge through the Leukotriene Pathway Am. J. Respir. Crit. Care Med., June 1, 2002; 165(11): 1540 - 1545. [Abstract] [Full Text] [PDF]

				R. S. Ames, D. Lee, J. J. Foley, A. J. Jurewicz, M. A. Tornetta, W. Bautsch, B. Settmacher, A. Klos, K. F. Erhard, R. D. Cousins, et al. Identification of a Selective Nonpeptide Antagonist of the Anaphylatoxin C3a Receptor That Demonstrates Antiinflammatory Activity in Animal Models J. Immunol., May 15, 2001; 166(10): 6341 - 6348. [Abstract] [Full Text] [PDF]

				S. S. Salvi, M. T. Krishna, A. P. Sampson, and S. T. Holgate The Anti-inflammatory Effects of Leukotriene-Modifying Drugs and Their Use in Asthma Chest, May 1, 2001; 119(5): 1533 - 1546. [Abstract] [Full Text] [PDF]

				D. C. Underwood, R. R. Osborn, S. Bochnowicz, E. F. Webb, D. J. Rieman, J. C. Lee, A. M. Romanic, J. L. Adams, D. W. P. Hay, and D. E. Griswold SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung Am J Physiol Lung Cell Mol Physiol, November 1, 2000; 279(5): L895 - L902. [Abstract] [Full Text] [PDF]

				A. R Leff Role of leukotrienes in bronchial hyperresponsiveness and cellular responses in airways Thorax, October 1, 2000; 55(90002): 32S - 37. [Full Text]

				A. KANEHIRO, K. TAKEDA, A. JOETHAM, A. TOMKINSON, T. IKEMURA, C. G. IRVIN, and E. W. GELFAND Timing of Administration of Anti-VLA-4 Differentiates Airway Hyperresponsiveness in the Central and Peripheral Airways in Mice Am. J. Respir. Crit. Care Med., September 1, 2000; 162(3): 1132 - 1139. [Abstract] [Full Text]

				P. Kesteven Traveller's thrombosis Thorax, August 1, 2000; 55(90001): S32 - 36. [PDF]

				S. FUKUYAMA, H. INOUE, H. AIZAWA, M. OIKE, M. KITAURA, O. YOSHIE, and N. HARA Effect of Eotaxin and Platelet-activating Factor on Airway Inflammation and Hyperresponsiveness in Guinea Pigs in Vivo Am. J. Respir. Crit. Care Med., June 1, 2000; 161(6): 1844 - 1849. [Abstract] [Full Text]

				M. Hojo, M. Suzuki, K. Maghni, Q. Hamid, W. S. Powell, and J. G. Martin Role of Cysteinyl Leukotrienes in CD4+ T Cell-Driven Late Allergic Airway Responses J. Pharmacol. Exp. Ther., May 1, 2000; 293(2): 410 - 416. [Abstract] [Full Text]

				D. C. Underwood, R. R. Osborn, C. J. Kotzer, J. L. Adams, J. C. Lee, E. F. Webb, D. C. Carpenter, S. Bochnowicz, H. C. Thomas, D. W. P. Hay, et al. SB 239063, a Potent p38 MAP Kinase Inhibitor, Reduces Inflammatory Cytokine Production, Airways Eosinophil Infiltration, and Persistence J. Pharmacol. Exp. Ther., April 1, 2000; 293(1): 281 - 288. [Abstract] [Full Text]

				J. F. Regal, D. G. Fraser, C. E. Weeks, and N. A. Greenberg Dietary Phytoestrogens Have Anti-Inflammatory Activity in a Guinea Pig Model of Asthma Experimental Biology and Medicine, April 1, 2000; 223(4): 372 - 378. [Abstract] [Full Text] [PDF]

				S.-E. DAHLEN Pharmacological Characterization of Leukotriene Receptors Am. J. Respir. Crit. Care Med., February 1, 2000; 161(2): S41 - 45. [Full Text] [PDF]

				A. R. LEFF Role of Leukotrienes in Bronchial Hyperresponsiveness and Cellular Responses in Airways Am. J. Respir. Crit. Care Med., February 1, 2000; 161(2): S125 - 132. [Full Text] [PDF]

				S. T. HOLGATE and A. P. SAMPSON Antileukotriene Therapy . Future Directions Am. J. Respir. Crit. Care Med., February 1, 2000; 161(2): S147 - 153. [Full Text] [PDF]

				T. HISADA, M. SALMON, Y. NASUHARA, and K. F. CHUNG Cysteinyl-leukotrienes Partly Mediate Eotaxin-induced Bronchial Hyperresponsiveness and Eosinophilia in IL-5 Transgenic Mice Am. J. Respir. Crit. Care Med., August 1, 1999; 160(2): 571 - 575. [Abstract] [Full Text]

				T. PULLERITS, L. PRAKS, B.-E. SKOOGH, R. ANI, and J. LÖTVALL Randomized Placebo-controlled Study Comparing a Leukotriene Receptor Antagonist and a Nasal Glucocorticoid in Seasonal Allergic Rhinitis Am. J. Respir. Crit. Care Med., June 1, 1999; 159(6): 1814 - 1818. [Abstract] [Full Text]

				M. A. Giembycz and M. A. Lindsay Pharmacology of the Eosinophil Pharmacol. Rev., June 1, 1999; 51(2): 213 - 340. [Abstract] [Full Text] [PDF]

				A. MULDER, G. M. GAUVREAU, R. M. WATSON, and P. M. O'BYRNE Effect of Inhaled Leukotriene D4 on Airway Eosinophilia and Airway Hyperresponsiveness in Asthmatic Subjects Am. J. Respir. Crit. Care Med., May 1, 1999; 159(5): 1562 - 1567. [Abstract] [Full Text] [PDF]

				D. C. Underwood, S. Bochnowicz, R. R. Osborn, C. J. Kotzer, M. A. Luttmann, D. W.P. Hay, P. D. Gorycki, S. B. Christensen, and T. J. Torphy Antiasthmatic Activity of the Second-Generation Phosphodiesterase 4 (PDE4) Inhibitor SB 207499 (Ariflo) in the Guinea Pig J. Pharmacol. Exp. Ther., December 1, 1998; 287(3): 988 - 995. [Abstract] [Full Text]

				P. J. Barnes, K. F. Chung, and C. P. Page Inflammatory Mediators of Asthma: An Update Pharmacol. Rev., December 1, 1998; 50(4): 515 - 596. [Abstract] [Full Text] [PDF]

				S. O'Sullivan, S.-E. Dahlen, K. Larsson, B.-M. Larsson, P. Malmberg, M. Kumlin, and L. Palmberg Exposure of healthy volunteers to swine house dust increases formation of leukotrienes, prostaglandin D2, and bronchial responsiveness to methacholine Thorax, December 1, 1998; 53(12): 1041 - 1046. [Abstract] [Full Text]

				W. W. BUSSE Leukotrienes and Inflammation Am. J. Respir. Crit. Care Med., June 1, 1997; 157(6): 210S - 213. [Abstract] [Full Text]

				D. AHARONY Pharmacology of Leukotriene Receptor Antagonists Am. J. Respir. Crit. Care Med., June 1, 1997; 157(6): 214S - 219. [Abstract] [Full Text]